- What Are Tactile Cues and How Do They Help Recovery? - 28 March 2026
- Parsonage-Turner Syndrome and COVID-19: What the Research Shows - 28 March 2026
- Managing Pain in the Acute Phase of Parsonage-Turner Syndrome - 28 March 2026
If there’s one thing the COVID-19 pandemic taught us, it’s that the immune system is capable of doing some truly unexpected things. For a small number of people, one of those unexpected things was developing Parsonage-Turner syndrome. Whether triggered by the infection itself or the vaccines designed to protect against it, we saw a noticeable uptick in PTS cases during the pandemic years.
This article is part of our comprehensive guide to Parsonage-Turner syndrome.
Before we go any further, let’s get something out of the way. This isn’t an anti-vaccine article. Parsonage-Turner syndrome has been associated with vaccinations for decades, long before COVID was ever on the scene [4][5]. The COVID vaccines didn’t invent this problem, they simply brought more attention to it. So let’s walk through what the research actually shows, who’s at risk, and what you should do if you suspect something isn’t right.
PTS After COVID-19 Infection
It’s easy to focus entirely on the vaccine angle, but COVID-19 infection itself appears to be a more significant trigger for neuralgic amyotrophy than the vaccines are. And the outcomes tend to be worse.
When it comes to post-infection PTS, the average onset of symptoms is around 20.3 days after the initial COVID infection [1]. That’s roughly three weeks of feeling like you’re recovering before suddenly being hit with severe, burning shoulder pain. For those unfamiliar with how PTS typically presents, this sudden onset of excruciating pain is the hallmark feature.
What’s particularly concerning is the recovery outlook. Only 38.9% of those who developed Parsonage Turner syndrome after COVID-19 showed even partial improvement [1]. That’s significantly lower than post-vaccination cases, and lower than the general PTS population too. It likely comes down to the sheer scale of immune activation during a full-blown infection compared to a targeted vaccine response. The collateral damage to the brachial plexus can be more extensive.
This matters because some people think avoiding vaccination protects them from PTS. It doesn’t. Catching COVID without vaccine protection may actually put you at greater risk of developing brachial neuritis, with a worse prognosis [6]. Infections have long been known to trigger immune-mediated nerve conditions, and hepatitis E virus has been particularly well-documented as a trigger for neuralgic amyotrophy [10]. COVID-19 has simply joined that list.
PTS After COVID-19 Vaccination
Yes, Parsonage-Turner syndrome has been documented after COVID vaccination. But the picture is actually more reassuring than you might expect.
The average onset after vaccination is 11.7 days [1], considerably quicker than post-infection onset. The vaccine provokes a targeted immune response that peaks quickly, so the immune-mediated nerve damage, when it does occur tends to happen in a more contained window.
And here’s the important bit: 78.1% of those who developed PTS after vaccination showed partial improvement [1]. That’s dramatically better than the 38.9% with post-infection cases. It suggests the underlying nerve damage may be less severe, the recovery trajectory appears more favourable.
However, “partial improvement” still isn’t full recovery. The acute pain phase can still be absolutely brutal, and the rehabilitation process is just as important as it would be for any other trigger. If you’re going through this, don’t let anyone dismiss your experience just because “it was only the vaccine.” The pain is real, the nerve damage is real. The condition predominantly affects males, though cases in females have been reported, with pain typically beginning in the shoulder and weakness following once the initial pain settles [2][3]. If this sounds familiar, getting into rehabilitation should be a priority.
Which Vaccines Are Involved?
In the reported cases, Pfizer-BioNTech accounts for roughly 53% of post-vaccination PTS cases, with AstraZeneca at around 29% [2]. But those numbers don’t tell you what you think they tell you. Pfizer was by far the most widely administered vaccine globally, so of course it appears most frequently in case reports. The proportions roughly mirror administration rates rather than indicating any difference in risk.
The mRNA vaccines (Pfizer, Moderna) and the viral vector vaccines (AstraZeneca, Johnson & Johnson) use completely different mechanisms, yet both have been associated with PTS. This strongly suggests it’s the immune response itself, not any specific vaccine ingredient, that’s the trigger [1][2]. For those with pre-existing anxiety around medical procedures, this uncertainty can feel particularly unsettling.
This is consistent with what we know historically. PTS has been documented after flu vaccines, tetanus shots, and a range of other immunisations [4][5]. It isn’t specific to any one vaccine technology.
What Does the Research Actually Say?
Let’s dig into the specific studies, because the details matter.
The Systematic Reviews
Haiy and colleagues (2023) systematically reviewed cases of PTS following COVID-19 vaccination [1], one of the more comprehensive reviews available. Cases were predominantly in males, aligning with the general epidemiology of neuralgic amyotrophy [4], with onset typically sudden and severe within two weeks. The left arm was affected more frequently than the right, which may partly reflect that most people receive vaccinations in their non-dominant arm.
Vitturi and colleagues (2021) contributed a case report of PTS following AstraZeneca vaccination [2], alongside a review of the existing literature. The patient presented with severe shoulder and upper arm pain followed by progressive weakness. MRI findings were consistent with typical PTS patterns, showing denervation changes and sometimes nerve inflammation on neurography [3]. This is important because it confirms post-vaccination PTS is the same condition as idiopathic PTS, not some novel vaccine injury.
Post-Vaccination vs Post-Infection
When we lay the two side by side, clear patterns emerge. Post-vaccination PTS tends to have shorter onset (11.7 days vs 20.3 days), better recovery rates (78.1% vs 38.9% showing improvement), and a more predictable clinical course [1]. It’s a bit like worrying about the side effects of a seatbelt while ignoring the windscreen.
However, we should acknowledge the data’s limitations. Case reports aren’t the same as large-scale epidemiological studies, and many cases of PTS go unrecognised or misdiagnosed regardless of trigger.
Recurrence With Subsequent Vaccinations
There are documented cases of PTS recurring with subsequent COVID vaccinations [1][7]. Van Alfen’s landmark study showed that recurrence is a known feature of neuralgic amyotrophy generally, with about 26% experiencing more than one episode [4]. When a known trigger has previously caused an episode, subsequent exposure may carry elevated risk. This should absolutely be discussed with your neurologist before receiving booster doses. We’re not saying don’t get boosted, we’re saying have the conversation and make an informed decision. That’s not anti-vaccine, that’s just good medicine.
Why Does This Happen?
Why would a vaccine (or an infection) trigger damage to the nerves of the brachial plexus? The answer lies in how the immune system sometimes gets its wires crossed, quite literally.
The leading theory involves molecular mimicry. When your immune system encounters a virus or vaccine, it produces antibodies targeted at specific proteins on the pathogen. But sometimes those proteins look remarkably similar to proteins on your own nerve tissue. The immune system, in its enthusiasm to fight the threat, accidentally attacks the nerves too [5]. It’s friendly fire, essentially. The brachial plexus seems particularly vulnerable, possibly because the local immune environment or the blood-nerve barrier in this region is more permeable than elsewhere [5].
There’s also bystander immune activation, where the general ramping up of the immune system leads to inflammation damaging nearby tissues as collateral. Think of a controlled burn that jumps the firebreak. And then there’s blood-nerve barrier disruption: inflammation can compromise the barrier’s integrity, allowing immune cells direct access to the nerve tissue [5].
None of these mechanisms are unique to COVID vaccines. They’re the same mechanisms that explain PTS after flu vaccines, surgical procedures, infections, even intense physical exertion [4][8]. There’s even a hereditary form linked to mutations in the SEPT9 gene that makes people more susceptible to these immune-mediated attacks [9]. It’s a bit like how some people get flare-ups from stress, illness, or overexertion. The trigger varies but the underlying vulnerability is the constant.
Should You Still Get Vaccinated?
Yes. Full stop.
PTS after vaccination is exceptionally rare, a handful of cases per million doses administered [1][2]. Meanwhile, COVID-19 itself carries a far greater risk of neurological complications, including PTS. When it comes to the risk-benefit calculation, it’s not even close.
However, there are nuances worth considering:
- If you’ve had PTS before (from any cause), discuss vaccination with your neurologist. The decision should be informed and individualised.
- If you developed PTS after a first dose, your doctor may recommend a different vaccine type for subsequent doses, or additional monitoring.
- If you have hereditary neuralgic amyotrophy (the SEPT9-linked form), you’re at higher risk of recurrence from any immune trigger, and this warrants a specialist conversation [9].
The goal isn’t to avoid vaccination. The goal is awareness so that if PTS does occur, it gets recognised and treated promptly rather than dismissed as a normal injection site reaction. This kind of informed approach to risk is something we should be doing with all medical decisions.
What To Do If You Suspect PTS After Vaccination
Early recognition can make a real difference to outcomes. Some shoulder pain after vaccination is completely expected, but there are red flags:
- Severe, disproportionate pain that goes well beyond normal injection site soreness, pain that keeps you awake at night.
- Pain that starts days to weeks after vaccination, rather than immediately. Normal pain peaks within 24-48 hours; PTS onset is typically 1-2 weeks later [1].
- Pain that radiates beyond the deltoid, spreading across the shoulder, down the arm, or into the shoulder blade region.
- Progressive weakness in the affected arm, particularly difficulty lifting, gripping, or performing overhead movements.
- Visible muscle wasting in the weeks following onset, particularly in the shoulder or upper arm.
If you’re experiencing any of these, don’t sit on it. Early treatment with corticosteroids may help reduce inflammatory damage, though the evidence is somewhat mixed [8]. Delayed diagnosis leads to delayed rehabilitation, and that affects long-term recovery. When you see your GP, be specific about your concern and ask for a neurology referral. Too many people go through weeks of medical runarounds before getting the right diagnosis.
Also be aware that SIRVA (Shoulder Injury Related to Vaccine Administration) is a different condition. SIRVA is a mechanical injury from incorrect needle placement, not an immune-mediated nerve condition. The key differences are timing (SIRVA starts immediately, PTS is delayed) and the presence of neurological symptoms like weakness.
Understanding how PTS is diagnosed can help you advocate for yourself. Once diagnosed, a structured rehabilitation programme is essential. Some people find supportive taping or compression garments helpful during recovery, though these aren’t substitutes for proper rehab.
Frequently Asked Questions
Is PTS from the COVID vaccine different from other forms of PTS?
Not really. The clinical presentation, nerve damage patterns, and recovery process are essentially the same regardless of trigger [1][4]. What might differ is severity and prognosis: post-vaccination PTS generally has a better recovery outlook than post-infection PTS. But in terms of treatment, there’s no meaningful difference. The same recovery phases apply, and the same rehabilitation approaches are recommended.
Should I get a booster if I had PTS after my first COVID vaccine dose?
This is a conversation you need to have with your neurologist, not something to decide based on an internet article. There are documented cases of PTS recurring with subsequent vaccinations [1][7], but the risk of COVID infection also isn’t zero, and post-infection PTS has worse outcomes. Your doctor can help weigh these factors based on your specific situation. Some specialists may recommend switching vaccine type, pre-treating with corticosteroids, or monitoring more closely. There’s no one-size-fits-all answer.
How common is PTS after COVID vaccination?
Extremely rare. Systematic reviews have identified only 42-59 cases globally from billions of doses [1][2]. For context, PTS in the general population occurs in roughly 2-3 per 100,000 people per year [4], and the vast majority aren’t vaccine-related. However, given what we know about COVID’s broader neurological effects, the small number of reported cases likely represents some underreporting.
Can COVID-19 infection itself cause PTS?
Absolutely. Multiple case reports have documented PTS developing after COVID-19 infection, with onset typically around 20 days post-infection [1][6]. Recovery rates are significantly lower than post-vaccination cases. This is consistent with other viral triggers, particularly hepatitis E [10]. When it comes to protecting yourself from PTS, vaccination actually appears to be the safer bet compared to unprotected infection.
Is it just SIRVA, or could it actually be PTS?
The two get confused more often than they should. SIRVA is caused by incorrect needle placement, causing localised inflammation that starts within 48 hours. PTS involves brachial plexus nerve damage, starts days to weeks later, and causes progressive weakness and muscle wasting. If pain started immediately and is localised to the joint area, it’s more likely SIRVA. If it started a week or more later with arm weakness, PTS needs to be on the radar. Either way, get it checked properly.
Living With PTS: The Bigger Picture
Whether your PTS was triggered by COVID, a vaccine, or something else, the path forward is largely the same. Understanding your condition, working through the phases of recovery, engaging with appropriate rehabilitation, and being patient with yourself. The complete Parsonage-Turner syndrome guide covers everything from diagnosis through to long-term management. If you’re struggling with pacing and energy management, those principles apply here just as much as for other chronic pain conditions.
For those with breathing difficulties or fatigue layered on top (especially with long COVID), understanding CO2 tolerance and breathlessness can be genuinely helpful. The COVID-PTS connection has been a silver lining of sorts, the increased research attention means diagnosis times are improving and more clinicians are recognising the condition. That benefits everyone with PTS. Understanding conditions like complex regional pain syndrome and other nerve-related pain conditions has taught us that early intervention matters enormously, and PTS is no different.
– The Fibro Guy Team –
Where to Go From Here
If you’re working through recovery from Parsonage-Turner syndrome, the principles we use in our studios — neuron-first rehab, sensory mapping, graded loading — are the same ones that underpin our Hypermobility 101 course. It covers the frameworks for rebuilding joint control and proprioception that are directly relevant to PTS recovery. Have a look through the full course library for everything we offer.
